Pfizer Inc.
NYSE: PFEKey stats
Price chart
About Pfizer Inc.
Pharmaceuticals
Company profile
- IPO date
- Jan 17, 1944
- Website
- www.pfizer.com
Healthcare peers
How PFE compares to other large companies in the same sector.
| Company | Price | Today | Market cap | P/E |
|---|---|---|---|---|
 LLY Eli Lilly and Company | $939.49 | -1.64% | $887.63B | 43.01 |
 JNJ Johnson & Johnson | $238.48 | -1.17% | $574.36B | 21.43 |
 ABBV AbbVie Inc. | $207.96 | -2.09% | $367.80B | 87.03 |
 MRK Merck & Co. | $121.44 | -1.01% | $300.20B | 16.45 |
 UNH UnitedHealth Group | $304.35 | -0.83% | $276.23B | 22.91 |
Wall Street analyst ratings
DollarScout analysis
Editorial, not advice. See our methodology.
Bull case
Pfizer is a pharmaceutical titan with a diverse portfolio that includes the popular COVID-19 vaccine, Comirnaty. Its well-established research and development arm is consistently working on expanding its drug pipeline, promising future growth. The company's current dividend yield of 6.3832% remains a significant attraction for income-seeking investors, particularly in low-interest-rate environments. With a P/E ratio of 19.7, its valuation appears reasonable compared to competitors in the healthcare sector. Furthermore, its low beta of 0.3537 indicates less volatility compared to the broader market, which may appeal to risk-averse investors.
Bear case
Pfizer faces stiff competition from other pharmaceutical giants like Moderna and Johnson & Johnson, potentially impacting market share and revenue growth. The company's reliance on blockbuster drugs like its COVID-19 vaccine introduces risk if demand wanes or if new, superior treatments emerge. Concerns about patent cliffs, where key drug patents expire, pose a threat to sustained revenue. Furthermore, regulatory challenges and the high cost of R&D could impact profitability, especially if key drug approvals face delays or denials. The current price trend is bullish, but any negative shift in sentiment or performance could swiftly change this trajectory.
Who should buy PFE
Pfizer is a solid fit for long-term dividend investors who have a moderate risk tolerance and are seeking stable income through high-yield dividends. It's also suitable for investors looking to add a defensive, large-cap healthcare name with a lower volatility profile to their portfolio.
Key risks
- Intense competition from pharmaceutical peers could affect market share. - Dependency on blockbuster drugs might backfire if demand decreases or competitors provide better alternatives. - Expiring drug patents may lead to revenue erosion. - Regulatory barriers and high R&D costs could hinder profitability.
Where to buy PFE
Open an account with a broker we've reviewed and start trading Pfizer Inc. today.
Want to practice first? Try the free Stock Trading Simulator with $100,000 virtual cash.
Recent PFE news
The choice is based on more than just the dividend payout.
Pfizer is seeking drug development partnerships with Chinese biotech companies as local players gain ground on Western peers. The company aims to broaden its research and development model beyond the U.S. and Europe through these China focused collaborations. This shift reflects both competitive pressure from China’s rapid biotech progress and the potential opportunity to expand Pfizer’s future drug pipeline. For investors watching NYSE:PFE at a share price of $26.92, this push into China...
In recent days, analysts have repeatedly flagged ongoing competitive and pricing pressures on Pfizer’s key products, including Paxlovid, Vyndamax and Prevnar, along with softer visibility for its COVID-19 vaccine franchise and pipeline execution risks. At the same time, Pfizer has been reshaping its portfolio through acquisitions, pipeline expansion and cost-saving efforts, creating a tension between product headwinds, dividend questions and its longer-term innovation ambitions. We’ll now...
China’s biotechs are faster and have lower costs, and its drug research threatens to soon overtake the West’s
The company has increased its payouts over the past five years despite significant challenges.
BMY stock jumps 10% in a month as growth drugs power revenues, but generic erosion and 2026 sales outlook keep investors cautious.
Amneal Pharmaceuticals taps GLP-1 growth via a Pfizer-linked manufacturing deal, gaining exposure without clinical risks while scaling injectables and peptides.
ABBV edges out PFE as Skyrizi and Rinvoq fuel strong growth, offsetting Humira losses and positioning the drugmaker for sustained expansion.
Disclaimer: The information on this page is provided for informational and educational purposes only and should not be considered financial, investment, or trading advice. DollarScout does not recommend buying or selling any specific security. Stock data may be delayed. Past performance is not indicative of future results. Always do your own research and consult a licensed financial advisor before making investment decisions.